Amgen overcomes insurance benefit for Blincyto

Published: 2016-09-21 17:18:31

Updated: 2016-09-21 17:18:31

It is expected Amgen will begin to aggressively target the domestic antibody market.

In the ‘Amendment to the Public Announcement about Drugs Prescribed and Administered on Cancer Patients’ notified by the Health Insurance Review & Assessment Service on the 19^th, a health insurance standard for an Amgen’s acute lymphocytic leukemia therapy ‘Blincyto(generic name: blinatumomab)’ was newly creat...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.